2digital Facebook ad: “𝗢𝘇𝗲𝗺𝗽𝗶𝗰 𝗔𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 𝗶𝗻 𝟮𝟬𝟮𝟲…”

About this ad

Meta Ad Library ID

25790195060673403

Platforms

Instagram

Relaunches

3

EU reach

6,603

How we count

Ad text

𝗢𝘇𝗲𝗺𝗽𝗶𝗰 𝗔𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 𝗶𝗻 𝟮𝟬𝟮𝟲: 𝗪𝗵𝗮𝘁 𝗖𝗮𝗻 𝗥𝗲𝗽𝗹𝗮𝗰𝗲 𝘁𝗵𝗲 𝗠𝗼𝘀𝘁 𝗙𝗮𝗺𝗼𝘂𝘀 𝗪𝗲𝗶𝗴𝗵𝘁-𝗟𝗼𝘀𝘀 𝗗𝗿𝘂𝗴? The rise in “ozempic alternatives” searches in 2026 stems from three factors: limited availability, high cost and treatment tolerability. We prepared an article that breaks down which drugs are realistically considered replacements for Ozempic, how they differ by active ingredient and dosing format, and why the question of semaglutide generics has become especially urgent. - Semaglutide and Novo Nordisk products. Ozempic (semaglutide) remains the best-known weight-loss drug, although it was originally developed to treat Type 2 diabetes. Alongside it is Wegovy, the semaglutide brand for weight loss, and Rybelsus, semaglutide in pill form — important for those who want to avoid injections on principle - Eli Lilly and tirzepatide. Mounjaro and Zepbound contain the active ingredient tirzepatide (GIP/GLP-1) and are considered the leading competitor to Ozempic/Wegovy. Studies suggest tirzepatide delivers greater weight loss for some patients, but in real-world use, the choice is shaped not only by peak percentages, but also by tolerability and the ability to stay on therapy long term - New entrants and an attempt to change the treatment schedule. In early 2026, Pfizer published midstage trial results for an experimental drug and emphasized a regimen in which, after a dose-finding phase, patients could potentially shift to once-monthly maintenance dosing. It’s a very convenient alternative, but the drug is still in trials Separately, the article examines the generics question. In Canada, the discussion has intensified as patent timelines approach their expiration in early 2026, raising expectations of more affordable semaglutide versions. At the same time, for injectable drugs, the legal end of patent protection does not mean the immediate arrival of mass-market, low-cost copies. By Dzmitry Korsak

Where the ad sends people